Form 4: Protagonist Therapeutics CFO Asif Ali Acquires Shares and Options

Protagonist Therapeutics' Chief Financial Officer, Asif Ali, acquired 31,779 shares of common stock and 38,520 stock options on January 2, 2025.

Summary

• Asif Ali, the Chief Financial Officer of Protagonist Therapeutics, acquired 31,779 shares of common stock on January 2, 2025.
• These shares were granted as restricted stock units, which will vest in four equal annual installments starting January 15, 2026.
• Mr. Ali also acquired 38,520 stock options on the same date, with an exercise price of $38.98.
• These options vest in 48 equal monthly installments following January 2, 2025, and expire on January 2, 2035.
• Both the stock units and options are subject to Mr. Ali's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock and options to the CFO aligns his interests with the long-term success of the company.
• The vesting schedules for both the stock units and options encourage continued service and commitment from the CFO.

Risks

• The value of the stock and options is dependent on the future performance of Protagonist Therapeutics.
• If Mr. Ali leaves the company before the vesting dates, he may forfeit some or all of the unvested shares and options.

Future Outlook

The vesting of the stock and options is contingent on the CFO's continued service with the company, suggesting a long-term commitment.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotech sector.

Comparison to Industry Standards

• Equity grants, including stock options and restricted stock units, are a common form of compensation for executives in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use similar equity-based compensation plans to align executive interests with shareholder value.
• The vesting schedules are typical, designed to retain talent and incentivize long-term performance.

Stakeholder Impact

• Shareholders may view this positively as it aligns the CFO's interests with the company's long-term performance.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Protagonist Therapeutics, Asif Ali, stock options, restricted stock units, insider trading, executive compensation, equity grants